Key facts
- Notable investors include Chicago Early Growth Ventures, Swan Peak Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for kēpos
- ·The full record, as it builds
Funding rounds
No funding rounds for kēpos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About kēpos
Producer of a human milk-derived nutritional formulation intended for gut and microbiome support. The company offers a bioidentical blend of human milk oligosaccharides and lactoferrin to reinforce gut barriers, regulate motility, and support immune responses, enabling health-conscious consumers to improve digestive resilience and overall well-being.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Chicago, IL, United States
- Founded
- 2023
- Website
- trykepos.com/
- Ownership
- Privately Held (backing)
kēpos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in kēpos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on kēpos in its N-PORT filings yet. We sweep new filings monthly.